2007 Fiscal Year Final Research Report Summary
The examination of the weakness factor of metabolic syndromes by the atypical antipsychotic
| Project/Area Number |
18591270
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | Hirosaki University |
|---|
Principal Investigator |
FURUKORI Norio Hirosaki University, Hirosaki University Hospital, Lecturer (20333734)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Keywords | Metabolic Syndrome / Adiopinectin / Olanzapine / Resperidone / Glucose metabolism / Glucose load test |
|---|
| Research Abstract |
Atypical antipsychotics has lower incidence of side effects such as extrapyramidal symptoms and oversadation, leading to the shortening of hospitalization or increasing quality of life. On the other hand, it has been concerned that the atypical antipsychotics induce weight gain and impaired glucose metabolism, which is associated with Life shortening. The application study conducted to compare glucose and lipid metabolism between atypical antipsychotics. The 38 schizophrenic patients receiving olanzapine or risperidone were tested using cookie loading test. Blood samplings were performed the just before and 60 and 120 min after the loading. Serum glucose, insulin, triglyceride, total cholesterol, HDL-cholesterol, LDL-chlesterol, leptin and lipoprotein were measured. No differences were found in age, gender and BMI between two medication groups. VLDL-cholesterol, triglyceride and lipoprotein in patients receiving olanzapine were significantly higher than those in patients receiving risperidone, whereas adiponectin in patients receiving olanzapine were significantly lower than in patients receiving risperidone. Inslinogenic index or HOMA-IR did not differ between the two groups. These findings suggested that olanzapine induce metabolic syndrome.
|
